Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.
Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.
Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.
In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.
For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Arcutis Biotherapeutics (Nasdaq: ARQT) outlined key clinical advancements and growth strategies during its Investor Day, emphasizing the upcoming launch of topical roflumilast ahead of the PDUFA action date on July 29. The company is poised for potential revenues of $1.8 billion to $3.8 billion in the U.S. dermatology segment by 2030. Current clinical trials show promising results in conditions like plaque psoriasis and seborrheic dermatitis, while the early pipeline includes ARQ-255 for alopecia areata expected to enter the clinic in 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) presents positive results from its Phase 2 study of roflumilast foam 0.3%, designed for seborrheic dermatitis treatment, during the 2022 American Academy of Dermatology annual meeting. The foam demonstrated a significant IGA success rate of 73.8% against 40.9% for the vehicle (p<0.0001) and improved patient quality of life across emotional, symptom, and functioning domains. The pivotal Phase 3 STRATUM trial is currently enrolling patients, with topline data expected mid-2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported positive pooled results from its Phase 3 DERMIS trials for roflumilast cream, a treatment aimed at plaque psoriasis. At week 8, 40% of patients achieved Investigator Global Assessment (IGA) success compared to 7% for the vehicle. Roflumilast cream demonstrated consistent efficacy across varying psoriasis severities and was well-tolerated, with low adverse events. Interim Phase 3 open-label study results revealed sustained efficacy over 32 weeks. The FDA has filed a New Drug Application for the cream, targeting a decision date of July 29, 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced an upcoming Investor Day scheduled for March 28, 2022, in Boston, MA, at 10:30 a.m. EDT. Presenters include CEO Frank Watanabe and other key executives, who will discuss the company’s strategic plans, including the launch of investigational roflumilast cream for plaque psoriasis and its applications for atopic dermatitis and seborrheic dermatitis. The event will be accessible via a live webcast, with an archive available later. Arcutis focuses on innovative solutions for immune-mediated dermatological conditions.
Frazier Life Sciences has successfully closed Frazier Life Sciences XI, L.P. (FLS XI), raising over $987 million, surpassing its target of $800 million. This fourth venture fund will continue focusing on biopharmaceuticals and innovative therapeutics through company creation and early-stage investments. Under the leadership of experienced partners, FLS XI follows the $617 million FLS X from 2020, adding to the firm’s total capital raised to over $3.1 billion. Frazier Life Sciences has supported numerous companies, including Phathom Pharmaceuticals (NASDAQ: PHAT) and Arcutis Biotherapeutics (NASDAQ: ARQT).
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 18,900 restricted stock units and options for 48,900 shares of its common stock to four new hires. These awards were authorized by the Compensation Committee and are part of the 2022 Inducement Plan, effective March 11, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $16.85 per share, equal to the closing price on the grant date. This move is aligned with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company specializing in immuno-dermatology, will participate in the upcoming Cowen 42nd Annual Health Care Conference on March 7, 2022. The fireside chat is scheduled for 2:50 p.m. EST. Interested investors can access the webcast via the Events section of the company's website.
Arcutis focuses on innovative treatments for immune-mediated dermatological diseases, currently advancing multiple clinical programs and has one NDA under FDA review.
Arcutis Biotherapeutics (ARQT) announced FDA acceptance of the NDA for roflumilast cream for plaque psoriasis treatment. The company completed enrollment for a pivotal Phase 3 trial in seborrheic dermatitis and is currently enrolling trials for atopic dermatitis and psoriasis. Arcutis secured $225 million in non-dilutive financing, extending its cash runway into 2024, supported by $388.6 million in cash and equivalents. Despite a net loss of $71.3 million for Q4 2021 and $206.4 million for the full year, Arcutis aims for a pivotal year with potential product launches in 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of subject enrollment in its STRATUM Phase 3 trial for topical roflumilast foam, targeting seborrheic dermatitis, a condition affecting over 10 million Americans. The trial aims to evaluate the safety and efficacy of roflumilast foam, with top-line results expected by mid-2022 and a potential NDA submission in the first half of 2023. This therapeutic approach represents a significant advancement, as current treatments are inadequate, especially for hard-to-treat areas like the scalp and face.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
What does Arcutis Biotherapeutics, Inc. specialize in?
What are the main products of Arcutis Biotherapeutics?
Where is Arcutis Biotherapeutics headquartered?
When was Arcutis Biotherapeutics founded?
What is ZORYVE?
What is the mechanism of action for ZORYVE?
What are Arcutis' latest achievements?
How is Arcutis ensuring long-term growth?
What are some of Arcutis' ongoing projects?
Where can I get more information about Arcutis Biotherapeutics?
